Market Overview

Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress

Share:

Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to be
Presented During Plenary Session at American Urological Association
Annual Meeting; Company to Host Conference Call in Conjunction with Data
Presentation in May 2018

Expected Operating Runway Extended into the First Quarter of 2019

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical
company developing next-generation antibody-drug conjugate (ADC)
therapies for the treatment of cancer, today reported key pipeline
progress and operating results for the quarter and year ended December
31, 2017.

"2017 was a year of significant developments for our company, and as we
look ahead, I am highly encouraged by what we have already achieved in
2018. Vicinium™, our lead product candidate, holds significant potential
in treating a range of cancers, and is well underway in a registration
trial for people with non-muscle invasive bladder cancer," said Stephen
Hurly, president and chief executive officer of Eleven Biotherapeutics.
"We recently completed enrollment in our Phase 3 VISTA trial, and we are
pleased that initial data from the first patients in the VISTA trial
were selected for an oral presentation at the American Urological
Association Annual Meeting. 2018 is set to be a transformative year, and
with the completion of our recent equity financing, we are capitalized
to continue advancing Vicinium. We look forward to assessing its
efficacy and safety in NMIBC, and exploring opportunities to expand its
utility in other indications and in combination regimens."

Recent Pipeline and Corporate Highlights

  • On March 23, 2018, Eleven Biotherapeutics closed a $10.0 million
    equity financing priced at-the-market. This financing, coupled with
    the proceeds from the company's $8.0 million public offering completed
    in November 2017, extends the company's cash runway into the first
    quarter of 2019 based on its current operating plan.
  • In March 2018, Eleven Biotherapeutics announced that enrollment was
    completed in the company's Phase 3 VISTA trial evaluating its lead
    product candidate, Vicinium, for the treatment of patients with
    non-muscle invasive bladder cancer (NMIBC) who have been previously
    treated with bacillus Calmette-Guérin (BCG).
  • In December 2017, a trial at the US National Cancer Institute (NCI) of
    Vicinium in combination with AstraZeneca's immune checkpoint
    inhibitor, Imfinzi® (durvalumab), for the treatment of
    NMIBC opened.
  • In September 2017, Eleven Biotherapeutics completed the manufacturing
    of all Vicinium necessary for its ongoing trials.

Upcoming Data Presentations

  • Present Preclinical Data at AACR: Eleven Biotherapeutics will
    present preclinical data from its deBouganin program at the 2018
    American Association for Cancer Research (AACR) Annual Meeting during
    two poster sessions. The company's systemically administered product
    candidates are designed using its proprietary de-immunized variant of
    the plant-derived cytotoxin bouganin, deBouganin. Details of the
    presentations are as following:
    • Poster Title: VB6-845d Tumor Cell Killing Elicits Biologic
      Features of Immunogenic Cell Death
      • Date and Time: April 16, 2018 from 1:00 to 5:00 p.m. CT
    • Poster Title: Engineering and Characterization of Anti-PSMA
      Humabody-DeBouganin Fusion Proteins
      • Date and Time: April 18, 2018 from 8:00 a.m. to 12:00
        p.m. CT
  • Present Data from Phase 3 VISTA Trial at AUA Annual Meeting:
    Eleven Biotherapeutics will present the first, topline data from its
    Phase 3 VISTA trial of Vicinium in patients with NMIBC who have been
    previously treated with BCG during a plenary session at this year's
    American Urological Association Annual Meeting being held in San
    Francisco. The data being presented are three-month data from an
    initial 75 patients in the trial. Details of the presentation are as
    follows:
    • Presentation Title: Phase 3 Study of Vicinium in
      BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Initial
      Results
      • Date and Time: Monday, May 21, 2018 at 11:00 a.m. PT

Fourth Quarter and Full-Year 2017 Financial
Results

  • Cash Position: Cash and cash equivalents were $14.7 million as
    of December 31, 2017, compared to $25.3 million as of December 31,
    2016, a decrease of $10.6 million, which was primarily driven by $17.6
    million in cash used by operating activities plus, $0.1 million in
    capital expenditures, partially offset by $7.1 million in cash
    provided through the November 2017 underwritten public offering.
  • Revenue: No revenue was recognized during the three months
    ended December 31, 2017, compared to $0.8 million for the same
    three-month period in 2016. Revenue was $0.4 million for the twelve
    months ended December 31, 2017, compared to $30.0 million for the same
    period in 2016. The decrease was primarily due to a decrease in
    license revenue as we recognized the upfront license fee and
    development milestone payment under the license agreement with Roche,
    relating to the execution of the license agreement and the successful
    submission of the IND application for EBI-031 during 2016, as well as
    a decrease in collaboration revenue from a terminated collaboration.
  • R&D Expenses: Research and development expenses were $3.1
    million for the three months ended December 31, 2017, compared to $2.8
    million for the same period in 2016. For the twelve months ended
    December 31, 2017 research and development expenses were $12.5 million
    compared to $13.5 million for the 2016 fiscal year. The decrease of
    $1.0 million was primarily due to a decrease in EBI-031 related
    development expenses of $3.0 million due to the license agreement with
    Roche in which Roche is responsible for all on-going development
    expenses, as well as a decrease of $1.7 million of isunakinra-related
    development expenses, which development activities are no longer
    ongoing. These decreases were partially offset by increases in
    Vicinium-related development expenses of $5.4 million, since the
    company's acquisition of Viventia Bio Inc. (Viventia) in September
    2016.
  • G&A Expenses: General and administrative expenses were $2.0
    million for the three months ended December 31, 2017, compared to $2.8
    million for the same period in 2016. For the twelve months ended
    December 31, 2017 general and administrative expenses were $8.1
    million compared to $14.7 million for fiscal 2016. The decrease of
    $6.7 million was primarily due to a reduction of professional fees as
    well as salaries and related costs for personnel, including
    stock-based compensation. For the year ended December 31, 2016, the
    company had higher professional fees related to the license agreement
    with Roche, the company's 2016 review of strategic alternatives and
    the acquisition of Viventia. In addition, for the year ended December
    31, 2016, the company recorded higher severance costs related to the
    acquisition of Viventia.
  • Net Income (Loss): Net loss was $6.6 million, or $0.22 per
    share, for the three months ended December 31, 2017, compared to net
    loss of $3.5 million, or $0.15 per share, for the same period in 2016.
    Net loss was $29.0 million, or $1.11 per share, for the twelve months
    ended December 31, 2017, compared to net income of $1.9 million, or
    $0.09 per share, for the same period in 2016. Fiscal 2016 was
    benefited by approximately $30.0 million in revenue under the
    company's license agreement with Roche while no comparable revenue was
    recognized during fiscal 2017.
  • Financial Guidance: Following Eleven Biotherapeutics' recent
    $10.0 million equity financing in March 2018, the company expects to
    have capital to fund its current operating plans into the first
    quarter of 2019; however, we have based this estimate on assumptions
    that may prove to be wrong, and our capital resources may be utilized
    faster than we currently expect.

About Vicinium™

Vicinium™, Eleven Biotherapeutics' lead product candidate, is a
next-generation antibody-drug conjugate (ADC) developed using the
company's proprietary Targeted Protein Therapeutics platform. Vicinium
is comprised of a recombinant fusion protein that targets epithelial
cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to
deliver a potent protein payload, Pseudomonas Exotoxin A (ETA).
Vicinium is constructed with a stable, genetically engineered peptide
linker to ensure the payload remains attached until it is internalized
by the cancer cell, which is believed to decrease the risk of toxicity
to healthy tissues, thereby improving its safety. In prior clinical
studies conducted by Eleven Biotherapeutics, EpCAM has been shown to be
overexpressed in non-muscle invasive bladder cancer (NMIBC) cells with
minimal to no EpCAM expression observed on normal bladder cells. Eleven
Biotherapeutics is currently conducting the Phase 3 VISTA trial,
designed to support the registration of Vicinium for the treatment of
NMIBC in patients who have previously received two courses of bacillus
Calmette-Guérin (BCG) and whose disease is now BCG-unresponsive.
Topline, three-month data from the trial are expected in mid-2018.
Additionally, Eleven Biotherapeutics believes that Vicinium's cancer
cell-killing properties promote an anti-tumor immune response that may
potentially combine well with immuno-oncology drugs, such as checkpoint
inhibitors. The activity of Vicinium in BCG-unresponsive NMIBC is also
being explored at the US National Cancer Institute in combination with
AstraZeneca's immune checkpoint inhibitor durvalumab.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a late-stage clinical company advancing
next-generation antibody-drug conjugate (ADC) therapies for the
treatment of cancer based on the company's Targeted Protein Therapeutics
platform. The company's lead program, Vicinium™, is currently in a Phase
3 registration trial for the treatment of non-muscle invasive bladder
cancer, with topline data expected in mid-2018. Vicinium incorporates a
tumor-targeting antibody fragment and a protein cytotoxic payload into a
single protein molecule designed to selectively and effectively kill
cancer cells while sparing healthy cells. For more information, please
visit the company's website at www.elevenbio.com.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans
and prospects for the Company, the Company's strategy, future
operations, and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties inherent in the
initiation and conduct of clinical trials, our ability to successfully
develop our product candidates and complete our planned clinical
programs, our ability to obtain marketing approvals for our product
candidates, expectations regarding our ongoing clinical trials,
availability and timing of data from clinical trials, whether interim
results from a clinical trial will be predictive of the final results of
the trial or results of early clinical studies will be indicative of the
results of future studies, the adequacy of any clinical models,
expectations regarding regulatory approvals; our ability to obtain
additional capital to continue to fund operations and other factors
discussed in the "Risk Factors" section of the Company's Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent the
Company's views as of the date hereof. The Company anticipates that
subsequent events and developments will cause the Company's views to
change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing the Company's views
as of any date subsequent to the date hereof.

 
ELEVEN BIOTHERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
                   
(unaudited)
Three Months Ended December 31, Twelve Months Ended December 31,

2017

2016

2017

2016

 
Total revenue $ - $ 825 $ 425 $ 29,981
Operating expenses:
Research and development 3,108 2,795 12,510 13,479
General and administrative 1,985 2,752 8,070 14,736
Loss (gain) from change in fair value of contingent consideration   1,500     (1,100 )   9,100     (1,100 )
Total operating expenses   6,593     4,447     29,680     27,115  
Loss (gain) from operations (6,593 ) (3,622 ) (29,255 ) 2,866
Other income (expense), net   46     96     226     (970 )
Net (loss) income before income taxes (6,547 ) (3,526 ) (29,029 ) 1,896
Provision for income taxes   -     5     -     5  
Net (loss) income and comprehensive (loss) income $ (6,547 ) $ (3,531 ) $ (29,029 ) $ 1,891  
Net (loss) income per share —basic $ (0.22 ) $ (0.15 ) $ (1.11 ) $ 0.09  

Weighted-average number of common shares used in net (loss) income
per share —basic

  30,385     24,296     26,105     21,083  
Net (loss) income per share —diluted $ (0.22 ) $ (0.15 ) $ (1.11 ) $ 0.09  

Weighted-average number of common shares used in net (loss) income
per share —diluted

  30,385     24,296     26,105     21,733  
 
 
ELEVEN BIOTHERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
             
December 31,
  2017     2016  
 
Assets
Current assets:
Cash and cash equivalents $ 14,680 $ 25,342
Prepaid expenses and other current assets   301     585  
Total current assets 14,981 25,927
Property and equipment, net 522 796
Restricted cash 10 10
Intangible assets 46,400 60,500
Goodwill 13,064 16,864
Other assets   120     -  
 
Total assets $ 75,097   $ 104,097  
 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 907 $ 1,667
Accrued expenses 3,813 1,774
Deferred revenue - 425
Due to related party   -     114  
Total current liabilities 4,720 3,980
Other liabilities 215 -
Warrant liability - 5
Deferred tax liability 12,528 16,335
Contingent consideration 39,600 45,100
 
Stockholders' equity:
Common stock 35 25
Additional paid-in capital 170,330 161,963
Accumulated deficit   (152,331 )   (123,311 )
Total stockholders' equity   18,034     38,677  
 
Total liabilities and stockholders' equity $ 75,097   $ 104,097  

View Comments and Join the Discussion!